Chronic Periodontitis, Head and Neck Cancer, Radiotherapy Side Effect
Conditions
Keywords
Chronic Periodontitis, Head and Neck Cancer, Radiotherapy
Brief summary
This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy (HNC post-RT).
Detailed description
The urokinase-type plasminogen activator receptor (uPAR) plays an essential function in leukocytes and endothelial homeostasis and, therefore, in the development of chronic periodontitis. The study enrolled 150 participants, 50 chronic periodontitis with head and neck cancer post radiotherapy (CP+HNC post-RT) patients, 50 chronic periodontitis (CP) without HNC patients, and 50 healthy controls. Clinical Attachment Loss (CAL), Probing Pocket Depth (PPD), Plaque Index (PI), and Gingival Bleeding Index (GBI) were recorded. An enzyme-linked immunosorbent assay (ELISA) was constructed to quantify serum (suPAR) levels.
Interventions
RADIATIONRadiation
HNCs patients who received radiotherapy was exposure (5700-7000 Gys) for fractions number (32-35) after 6 months
Sponsors
Al-Maarif University College
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
28 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* A pathologically confirmed malignant neoplasm of HNC (derived from epithelial cells). * Not having received radiation therapy previously. * No distant metastasis. * No history of salivary gland surgery (parotid, submandibular, or sublingual). * A generally satisfactory physical condition with a performance score of 0 to 1 point and a planned survival period of more than a year and scores of 2 higher indicating increasing disability.
Exclusion criteria
* Previous oral disease or salivary gland disease history. * Definitive diagnosis of multiple sclerosis, xerostomia, or systemic disease. * Refusal to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure of serum suPAR level | 6 months | Measure of serum suPAR level in patients head and neck cancer who received radiotherapy |
| Clinical Periodontal parameters measured | 6 months | Periodontal parameters included (CAL, PI, GBI, PPD) measured by using a millimeter periodontal probe in patients with head and neck cancer who received radiotherapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Oral pH-saliva was measured | 6 month | Oral pH-saliva collected from outcomes and measured pH-saliva by using pH-meter in patients who underwent radiotherapy. |
Countries
Iraq
Outcome results
None listed